Background: The current study aimed to determine the oncological efficacy and surgical safety of multiple pulmonary resections (MPRs) after prior curative surgery for local regional recurrent or second primary lung cancers. Methods: All cases of lung cancer included in our prospective database between January 2000 and July 2015 were retrospectively reviewed. The oncological efficacy endpoints for synchronous and metachronous MPR were fiveyear overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS) rates after the second surgery. The surgical safety endpoints were postoperative mortality and complications (Clavien-Dindo classification) within 30 days. Results: In total, 67 MPR cases were identified. There were no significant differences in the five-year OS and DFS between the synchronous MPR group (n = 50) and the propensity score-matched solitary major pulmonary resection group (n = 250) (5-year OS 84.5% vs. 69.0%, log rank P = 0.112; DFS 64.4% vs. 58.0%, log rank P = 0.278). The five-year OS and PFS of the metachronous MPR group (n = 17) were significantly better than those in the non-surgical control group (n = 19) (5-year OS 94.1% vs. 50.7%, log rank P = 0.005; 5-year PFS 53.9% vs. 10.5%, log rank P = 0.020). No postoperative mortality or severe complications occurred in the MPR group. Conclusion: The oncological efficacy of MPR is superior to the non-surgical approach for the management of local regional recurrent or second primary lung cancer, with comparable postoperative mortality and complications.
Introduction
Although the repeated pulmonary resections of local regional recurrent or second primary lung cancers have long been performed in clinical practice, little is known about their oncological effectiveness and surgical safety. With the development of modern medical imaging, minimally invasive surgery, molecular pathology, and systematic treatment for lung cancer, multiple pulmonary resections (MPRs) are frequently performed in modern clinical practice. MPRs are suitable for a wide range of applications, including the following: (i) the curative management of multiple primary lung cancer (synchronous and metachronous), in conjunction with the widespread utilization of lung cancer screening and intense follow-up after prior surgery; (ii) a local consolidation treatment modality in the era of oligometastasis and oligorecurrence; (iii) the removal of residual disease after systematic treatment, such as chemotherapy, targeted therapy, or immunotherapy; and (iv) the robust tissue retrieval approach for precise staging and molecular analysis, compared with fine needle aspiration. In this study, we reviewed more than 1800 primary lung cancer cases from our prospective lung cancer database and determined the oncological efficacy and surgical safety of MPR for local regional recurrent or second primary lung cancers.
Methods and patients
The data of all primary lung cancer patients included in our prospective database between January 2000 and July 2015 were consecutively reviewed to identify MPR cases. The inclusion criteria were as follows: (i) patients who underwent either synchronous or metachronous MPR, and (ii) patients who had at least one tumor that was pathologically confirmed as primary lung cancer. Any patients who underwent bilobectomy via a single procedure because of the involvement of two neighboring lobes were excluded.
A propensity score-matched group of patients who underwent solitary major pulmonary resection (case-control ratio 1:5) was used as the control group for comparison with the synchronous MPR group in terms of survival. All patients with local regional recurrent or second primary lung cancer after the prior operation treated with a non-surgical approach were used as the control group for comparisons with the metachronous MPR group in terms of survival. The control group for surgical safety consisted of solitary major pulmonary resection patients.
Diagnosis, staging, and follow-up protocols
Our diagnostic, staging, and follow-up protocols for patients with lung cancer at Peking University Cancer Hospital include contrast-enhanced chest computed tomography (CT) including bilateral adrenals with or without CT-guided transthoracic biopsy, bilateral supraclavicular and upper abdominal ultrasonography, cranial magnetic resonance imaging, whole-body bone scintigraphy or positron emission tomography-CT, and flexible bronchoscopy with or without transbronchial biopsy. Other appropriate studies were performed to exclude extrapulmonary primary cancer that might affect the diagnoses and treatment options.
When resection was contemplated, a full biochemical analysis, an electrocardiogram, and pulmonary function tests were obtained. In addition, all patients evaluated for the repeated surgery had a second quantitative pulmonary function test to estimate the postoperative maximum forced expiratory volume in 1 second and the percentage of forced vital capacity. All lesions were clinically and pathologically staged according to the eighth edition of the International Staging System of Lung Cancer as proposed by the American Joint Committee on Cancer. 1 All patients who underwent resection for lung cancer at our institution were followed-up at the outpatient clinic quarterly for the first two years, semiannually for the following two years, and annually thereafter for life. Patient history and a physical examination along with a chest CT scan and bilateral supraclavicular and upper abdominal ultrasonography were obtained at each clinic visit. Moreover, whole-body bone scintigraphy or positron emission tomography-CT scan and cranial magnetic resonance imaging were obtained every six months.
Study endpoints
The oncological efficacy endpoints were as follows: (i) overall survival (OS) was calculated from the date of the first operation to the date of last follow-up or death; (ii) disease-free survival (DFS) of synchronous MPR was calculated from the date of the first operation to the date of the last follow-up, disease relapse, or death; and (iii) progression-free survival (PFS) of metachronous MPR was calculated from the date of local regional disease relapse/second primary lung cancer to the date of last follow-up, disease relapse, or death. The objective Response Evaluation Criteria in Solid Tumors version 1.1 was used to categorize response. 2 The final followup was conducted in September 2017.
The surgical safety endpoints were as follows: (i) postoperative mortality, including death from any cause, occurring within 30 days of surgery or beyond 30 days during the same hospitalization; and (ii) the definitions of postoperative complications were in accordance with those of the Society of Thoracic Surgeons General Thoracic Surgery Database, 3 while the severity of postoperative complications was evaluated by the Clavien-Dindo classification. 4 
Statistical analysis
The survival probability was calculated by the Kaplan-Meier actuarial method, with the date of procedure as the starting point, and including death from any causes. The log rank test was used to compare survival rates between groups. A P value of 0.050 was considered statistically significant. Propensity score matching was used to reduce bias in the comparison of MPR to a non-randomized control group. SAS version 9.2 (SAS Institute Inc., Cary, NC, USA) was used to perform statistical analysis. An SAS Macro, OneToManyMTCH, was applied to complete the 1:5 case-control propensity score matching. The graphs were prepared using GraphPad Prism version 6.01 (GraphPad Software Inc., La Jolla, CA, USA).
Results
Sixty-seven MPR cases (42 men and 25 women) were identified among the 1887 primary lung cancer patients in our prospective database between January 2000 and July 2015. The median age at initial diagnosis was 62 years (range: 35-77). Twenty-one patients (31%) had a history of smoking at the time of the first primary lung Among the 17 metachronous MPR patients, there were 14 patients at stage N0, 1 at stage N1, and 2 patients at stage N2 at the first resection and 17 patients at stage N0 at the second resection. Ten (15%) patients received neoadjuvant therapy and 24 (36%) received adjuvant therapy. The median duration of follow-up after the first operation was 53 months (range: 7-235) ( Table 1) .
The predominant extent of resection was lobectomy plus sublobar resection (46 patients, 70%), followed by lobectomy plus lobectomy (13 patients, 19%) . Among the 50 synchronous and 17 metachronous MPR patients, 29 (58%) and 13 (76%) underwent wedge resection, respectively. Among 17 patients who underwent synchronous MPR for bilateral lungs, the following five surgical strategies were used: (i) sublobar resection followed by lobectomy (n = 10); (ii) lobectomy followed by lobectomy (n = 2); (iii) lobectomy followed by sublobar resection (n = 3); (iv) sublobar resection followed by sublobar resection (n = 1); and (v) other treatment strategies, including chest wall resection (n = 1) ( Table 2 ).
The oncological efficacy of MPR
Fifty of the 67 patients (75%) underwent synchronous MPR, with a median follow-up duration of 43 months. The median OS and DFS were 146 and 70 months, respectively. The five-year OS and DFS were 83.3% and 66.2%, respectively. There were no significant differences in fiveyear OS and DFS between the patients who underwent MPR and the 250 propensity score-matched patients (1:5) who underwent solitary major pulmonary resection and were matched based on age, gender, histological type, clinical tumor node metastasis stage, and neoadjuvant therapy (5-year OS 84.5% vs. 69.0%, log rank P = 0.112; DFS 64.4% vs. 58.0%, log rank P = 0.278) (Fig 1) .
Seventeen of the 67 patients (25%) underwent metachronous MPR. Their five-year OS after the first operation was 94.1%, which was significantly better than that of the non-surgical control group (5-year OS 50.7%, log rank P = 0.005). The five-year PFS after the second operation was 53.9%, whereas the five-year PFS in the non-surgical control group (n = 19) was only 10.5% (log rank P = 0.020).
The surgical safety of MPR
No postoperative death occurred among the 67 patients with MPR. The most common postoperative complications were: atelectasis (4.5%), pneumonia (3.0%), prolonged air leak (3.0%), and pleural effusion (3.0%); there were no complications graded higher than IIIa. Between 2010 and 2014, 1112 solitary lung cancer patients underwent major pulmonary resections in our prospective database. The proportions of grade I-II and grade IIIa complications were 7.3% (81/1112) and 3.1% (34/1112), respectively.
Discussion
The standard surgery for lung cancer is anatomic pulmonary resection, and non-surgical treatment is traditionally chosen for local regional recurrent or second primary lung cancer after initial pulmonary resection because of the difficulty of a second operation and poor pulmonary function capacity. With the advances in multiple specialties related to lung cancer treatment, repeated pulmonary resections for local regional recurrent or second primary lung cancer after prior surgery have become clinically commonplace in thoracic surgery. However, little is known about the long- term survival of patients who undergo MPR. The surgical safety of MPR is another issue of great significance.
The oncological efficacy of synchronous MPR
The current study included a total of 50 patients who underwent synchronous MPR; their five-year OS and DFS were 83.3% and 66.2%, respectively. The differences in five-year OS and DFS between the synchronous MPR group and the matched control group (n = 250) were not statistically significant. Moreover, the survival results in this study were similar to those in relevant previous reports (Table 3 ). This indicates that except for those with confirmed poor prognostic features, such as N2/N3 stage, all synchronous multiple pulmonary lesions should be treated as multiple primary lung cancer instead of pulmonary metastasis because patients with multiple primary lung cancer can obtain favorable long-term survival after aggressive local treatment. Additionally, the principle of resection sequence for bilateral multifocal lesions was introduced in our previous retrospective study, with a higher priority given to sublobar resections of minor lesions located in the subdominant lobes and a lower priority to lobectomies of major lesions located in the dominant lobes.
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The oncological efficacy of metachronous MPR
The five -year OS of the 17 patients who underwent metachronous MPR was 94.1%, and the five-year PFS after the second operation was 53.9%, both of which were significantly better survival outcomes than those of the nonsurgical control group and the outcomes presented in previous reports (Table 3) . ADC (62) In our previous study, we retrospectively reviewed the data of 416 consecutive stage I non-small cell lung cancer patients in our prospective database who underwent major pulmonary resections between 2000 and 2013 by a single surgeon team. 29 A total of 76 cases (18.3%) had local regional recurrence or remote metastasis during the follow-up period, and the most frequent site of recurrence was the lung (21 cases, 5%). The accumulated two and five-year pulmonary recurrence rates were 2.3% (95% confidence interval 0.7-3.9%) and 4.8% (95% confidence interval 2.6-7.0%), respectively. These results indicate that postoperative follow-up for lung cancer patients is necessary in order to detect local regional recurrence, remote metastasis, and second primary lung cancer as early as possible. As long as the pulmonary function reserve is adequate without high-risk comorbidities, an aggressive surgical treatment could also provide more favorable long-term survival.
Postoperative safety of MPR
In the current study, we carefully reviewed the data of 67 patients with MPR and found there was neither postoperative mortality within 30 days nor severe postoperative complications greater than grade IIIa among both synchronous and metachronous MPR cases. The overall postoperative complication rate of the whole group was 9.3%, which was similar to the rate in patients that underwent solitary major pulmonary resections (10.3%). 30 This result was also similar to those of previous reports ( Table 3 ), indicating that the surgical safety of MPR is comparable to that of solitary major pulmonary resections.
In summary, to circumvent the issue of the difficulty of differential diagnosis between metastatic or second primary lung cancers, as long as rigorous selection criteria based on tumor biology and surgical principles are followed, MPR is potentially safe and effective. Of course, the current study has some limitations. First, although the clinical data were derived from our prospective lung cancer database, selection bias is innate to the retrospective nature of the study. Second, the limited number of non-surgery cases made propensity score matching infeasible, which could have resulted in inappropriate results and conclusions. Third, the small sample size undermines the reliability of the study results.
Nevertheless, these promising results justify planning a multicenter trial involving a larger cohort of patients. This study provides pilot data to enable more accurate power calculations to determine the required sample size for the desired outcome measures.
